FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Yoshifumi Takei

Research Profile

Living Beings

Chemicals & Drugs

Procedures

Physiology

Transfection

Phenomena

Blotting, Western

Anatomy

Disorders

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Y Suzuki; Yoshiro Fujita; Enyu Imai; Yasuhiko Ito; Hiroshi Kinashi; Shoichi Maruyama; Katsuyuki Matsui; Seiichi Matsuo; Masashi Mizuno; Tomohiro Mizuno; Yukihiro Noda; Akiho Sawai; Hideaki Shimizu; Yoshifumi Takei
Transforming growth factor-β induces vascular endothelial growth factor-C expression leading to lymphangiogenesis in rat unilateral ureteral obstruction.
Naoshi Koide; Kenji Kadomatsu; Kaori Yasuda; Yoshifumi Takei
Establishment and optimal culture conditions of microrna-induced pluripotent stem cells generated from HEK293 cells via transfection of microrna-302s expression vector.
Shinichiro Inaba; Takuji Ishimoto; Kenji Kadomatsu; Naoki Makita; Seiichi Matsuo; Shunji Nagahara; Yuzo Tarumi; Yoshifumi Takei
Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Yoshifumi Takei (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2012: Y Suzuki; Yoshiro Fujita; Enyu Imai; Yasuhiko Ito; Hiroshi Kinashi; Shoichi Maruyama; Katsuyuki Matsui; Seiichi Matsuo; Masashi Mizuno; Tomohiro Mizuno; Yukihiro Noda; Akiho Sawai; Hideaki Shimizu; Yoshifumi Takei
Transforming growth factor-β induces vascular endothelial growth factor-C expression leading to lymphangiogenesis in rat unilateral ureteral obstruction.
Kidney international 2012;81(9):865-79.
2012: Naoshi Koide; Kenji Kadomatsu; Kaori Yasuda; Yoshifumi Takei
Establishment and optimal culture conditions of microrna-induced pluripotent stem cells generated from HEK293 cells via transfection of microrna-302s expression vector.
Nagoya journal of medical science 2012;74(1-2):157-65.
2012: Shinichiro Inaba; Takuji Ishimoto; Kenji Kadomatsu; Naoki Makita; Seiichi Matsuo; Shunji Nagahara; Yuzo Tarumi; Yoshifumi Takei
Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals.
Molecular therapy : the journal of the American Society of Gene Therapy 2012;20(2):356-66.
2011: Yoshifumi Takei; Misato Takigahira; Keichiro Mihara; Yuzo Tarumi; Kazuyoshi Yanagihara
The metastasis-associated microRNA miR-516a-3p is a novel therapeutic target for inhibiting peritoneal dissemination of human scirrhous gastric cancer.
Cancer research 2011;71(4):1442-53.
2009: Ping Mu; Shunji Nagahara; Naoki Makita; Yuzo Tarumi; Kenji Kadomatsu; Yoshifumi Takei
Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer.
International journal of cancer. Journal international du cancer 2009;125(12):2978-90.
2009: Izumi Sakamoto; Yasuhiko Ito; Masashi Mizuno; Y Suzuki; Akiho Sawai; Akio Tanaka; Shoichi Maruyama; Yoshifumi Takei; Yukio Yuzawa; Seiichi Matsuo
Lymphatic vessels develop during tubulointerstitial fibrosis.
Kidney international 2009;75(8):828-38.
2008: Takuji Ishimoto; Yoshifumi Takei; Yukio Yuzawa; Koji Hanai; Shunji Nagahara; Yuzo Tarumi; Seiichi Matsuo; Kenji Kadomatsu
Downregulation of monocyte chemoattractant protein-1 involving short interfering RNA attenuates hapten-induced contact hypersensitivity.
Molecular therapy : the journal of the American Society of Gene Therapy 2008;16(2):387-95.
2008: Yoshifumi Takei; Toshio Nemoto; Ping Mu; Tatsuya Fujishima; Takuji Ishimoto; Yasuhiko Hayakawa; Yukio Yuzawa; Seiichi Matsuo; Takashi Muramatsu; Kenji Kadomatsu
In vivo silencing of a molecular target by short interfering RNA electroporation: tumor vascularization correlates to delivery efficiency.
Molecular cancer therapeutics 2008;7(1):211-21.
2007: Sen Chen; Guojun Bu; Yoshifumi Takei; Kazuma Sakamoto; Shinya Ikematsu; Takashi Muramatsu; Kenji Kadomatsu
Midkine and LDL-receptor-related protein 1 contribute to the anchorage-independent cell growth of cancer cells.
Journal of cell science 2007;120(Pt 22):4009-15.
2006: Hiroshi Banno; Yoshifumi Takei; Takashi Muramatsu; Kimihiro Komori; Kenji Kadomatsu
Controlled release of small interfering RNA targeting midkine attenuates intimal hyperplasia in vein grafts.
Journal of vascular surgery 2006;44(3):633-41.
2006: Yoshifumi Takei; Kenji Kadomatsu; Tatsunori Goto; Takashi Muramatsu
Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts.
Cancer 2006;107(4):864-73.
2006: Tomoki Kosugi; Yukio Yuzawa; Waichi Sato; Hanayo Kawai; Seiichi Matsuo; Yoshifumi Takei; Takashi Muramatsu; Kenji Kadomatsu
Growth factor midkine is involved in the pathogenesis of diabetic nephropathy.
The American journal of pathology 2006;168(1):9-19.
2005: Kenji Hayashi; Hiroshi Banno; Kenji Kadomatsu; Yoshifumi Takei; Kimihiro Komori; Takashi Muramatsu
Antisense oligodeoxyribonucleotide as to the growth factor midkine suppresses neointima formation induced by balloon injury.
American journal of physiology. Heart and circulatory physiology 2005;288(5):H2203-9.
2005: Yoshifumi Takei; Kenji Kadomatsu; Kanako Yuasa; Waichi Sato; Takashi Muramatsu
Morpholino antisense oligomer targeting human midkine: its application for cancer therapy.
International journal of cancer. Journal international du cancer 2005;114(3):490-7.
2005: Waichi Sato; Yoshifumi Takei; Yukio Yuzawa; Seiichi Matsuo; Kenji Kadomatsu; Takashi Muramatsu
Midkine antisense oligodeoxyribonucleotide inhibits renal damage induced by ischemic reperfusion.
Kidney international 2005;67(4):1330-9.
2004: Hanayo Kawai; Waichi Sato; Yukio Yuzawa; Tomoki Kosugi; Seiichi Matsuo; Yoshifumi Takei; Kenji Kadomatsu; Takashi Muramatsu
Lack of the growth factor midkine enhances survival against cisplatin-induced renal damage.
The American journal of pathology 2004;165(5):1603-12.
2004: Yoshifumi Takei; Kenji Kadomatsu; Yukio Yuzawa; Seiichi Matsuo; Takashi Muramatsu
A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics.
Cancer research 2004;64(10):3365-70.
2002: Yoshifumi Takei; Kenji Kadomatsu; Hiroshi Itoh; Waichi Sato; Kunihiko Nakazawa; Shunichiro Kubota; Takashi Muramatsu
5'-,3'-inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine. Its design and application for cancer therapy.
The Journal of biological chemistry 2002;277(26):23800-6.
2002: Onrai Matsuura; Kenji Kadomatsu; Yoshifumi Takei; Kenji Uchimura; Shunji Mimura; Kazuyoshi Watanabe; Takashi Muramatsu
Midkine expression is associated with postnatal development of the lungs.
Cell structure and function 2002;27(2):109-15.
2001: Yoshifumi Takei; Kenji Kadomatsu; Seiichi Matsuo; H Itoh; K Nakazawa; S Kubota; Takashi Muramatsu
Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells.
Cancer research 2001;61(23):8486-91.
1997: Toshimitsu Niwa; T Katsuzaki; Y Ishizaki; F Hayase; T Miyazaki; T Uematsu; N Tatemichi; Yoshifumi Takei
Imidazolone, a novel advanced glycation end product, is present at high levels in kidneys of rats with streptozotocin-induced diabetes.
FEBS letters 1997;407(3):297-302.
1997: Toshimitsu Niwa; T Katsuzaki; S Miyazaki; T Miyazaki; Y Ishizaki; F Hayase; N Tatemichi; Yoshifumi Takei
Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients.
The Journal of clinical investigation 1997;99(6):1272-80.
1997: Toshimitsu Niwa; T Katsuzaki; N Tatemichi; Yoshifumi Takei
Hyperlipidemia and tissue contents of N epsilon-(carboxymethyl)lysine in streptozotocin diabetes.
Contributions to nephrology 1997;120():132-9.
1997: Toshimitsu Niwa; T Katsuzaki; S Miyazaki; T Momoi; Takashi Akiba; T Miyazaki; Kazuya Nokura; F Hayase; N Tatemichi; Yoshifumi Takei
Amyloid beta 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis.
Kidney international 1997;51(1):187-94.
1996: Toshimitsu Niwa; M Sato; T Katsuzaki; T Tomoo; T Miyazaki; N Tatemichi; Yoshifumi Takei; T Kondo
Amyloid beta 2-microglobulin is modified with N epsilon-(carboxymethyl)lysine in dialysis-related amyloidosis.
Kidney international 1996;50(4):1303-9.
1996: Toshimitsu Niwa; T Katsuzaki; T Momoi; T Miyazaki; H Ogawa; A Saito; S Miyazaki; K Maeda; N Tatemichi; Yoshifumi Takei
Modification of beta 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum.
Kidney international 1996;49(3):861-7.
1996: Toshimitsu Niwa; T Miyazaki; T Katsuzaki; N Tatemichi; Yoshifumi Takei
Serum levels of 3-deoxyglucosone and tissue contents of advanced glycation end products are increased in streptozotocin-induced diabetic rats with nephropathy.
Nephron 1996;74(3):580-5.
1995: Toshimitsu Niwa; S Miyazaki; T Katsuzaki; N Tatemichi; Yoshifumi Takei; T Miyazaki; T Morita; Y Hirasawa
Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis.
Kidney international 1995;48(3):771-8.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.